- Home
- SPRO vs JHI Comparison
SPRO vs JHI Comparison
Compare SPRO & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- JHI
- Stock Information
- Founded
- SPRO 2013
- JHI 1971
- Country
- SPRO United States
- JHI United States
- Employees
- SPRO N/A
- JHI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- JHI Trusts Except Educational Religious and Charitable
- Sector
- SPRO Health Care
- JHI Finance
- Exchange
- SPRO Nasdaq
- JHI Nasdaq
- Market Cap
- SPRO 128.9M
- JHI 125.7M
- IPO Year
- SPRO 2017
- JHI N/A
- Fundamental
- Price
- SPRO $2.36
- JHI $13.83
- Analyst Decision
- SPRO Buy
- JHI
- Analyst Count
- SPRO 4
- JHI 0
- Target Price
- SPRO $5.00
- JHI N/A
- AVG Volume (30 Days)
- SPRO 1.2M
- JHI 29.5K
- Earning Date
- SPRO 11-13-2025
- JHI 01-01-0001
- Dividend Yield
- SPRO N/A
- JHI 6.80%
- EPS Growth
- SPRO N/A
- JHI N/A
- EPS
- SPRO N/A
- JHI 1.05
- Revenue
- SPRO $48,576,000.00
- JHI N/A
- Revenue This Year
- SPRO N/A
- JHI N/A
- Revenue Next Year
- SPRO N/A
- JHI N/A
- P/E Ratio
- SPRO N/A
- JHI $12.47
- Revenue Growth
- SPRO N/A
- JHI N/A
- 52 Week Low
- SPRO $0.51
- JHI $11.63
- 52 Week High
- SPRO $3.22
- JHI $13.40
- Technical
- Relative Strength Index (RSI)
- SPRO 57.47
- JHI 46.22
- Support Level
- SPRO $2.16
- JHI $13.64
- Resistance Level
- SPRO $2.44
- JHI $13.90
- Average True Range (ATR)
- SPRO 0.12
- JHI 0.14
- MACD
- SPRO -0.00
- JHI 0.02
- Stochastic Oscillator
- SPRO 55.24
- JHI 43.10
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.